BH7-HM173-100μg / 询价

BH7-HM173-500μg / 询价

BH7-HM173-1mg / 询价

Human B7-H3/CD276 Protein

产品信息(Product Info)

Recombinant Human B7-H3/CD276 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Leu29-Pro245.[Accession | Q5ZPR3-2]

分子量大小(Molecular Weight)

The protein has a predicted MW of 24.7 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-20 to -80°C for 3-6 months in unopened state after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human B7-H3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human B7-H3 is greater than 95% as determined by SEC-HPLC.


Immobilized Human B7-H3, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-B7-H3 Antibody, hFc Tag with the EC50 of 29.4ng/ml determined by ELISA.


B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig‑B7‑H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.


B7H3; B7-H3; CD276; PSEC0249; UNQ309; PRO352; B7 homolog 3; CD276


(1)Fodstad O , Tekle C , Chen Y W. The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion[J]. Current Cancer Drug Targets, 2008, 8(5)

(2)Du H, Hirabayashi K, Ahn S, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells[J]. Cancer Cell, 2019, 35(2).